PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 6, 2026One Health Advances0 citationsOpen Access

Nanoenabled smart drug delivery in One Health: advances in targeted therapy and theranostics

View Full Paper
OOOlalekan John OkesanyaUAUthman Okikiola AdebayoLHLawal Akorede Habeeb

Key Points

  • The review aims to synthesize evidence on nano-enabled smart drug delivery systems within the One Health framework for managing vector-borne diseases.
  • Reviewed various nano-enabled platforms including liposomes and nanoparticles.
  • Evaluated controlled-release formulations of therapeutic agents like artemisinin and ivermectin.
  • Discussed targeted delivery strategies for both human and animal health.
  • Examined theranostics combining imaging and therapy for early disease detection.
  • Controlled-release formulations improved treatment efficacy for malaria and leishmaniasis.
  • Targeted delivery strategies effectively addressed viral reservoirs and arthropod vectors.
  • Nanotechnology applications spanned human, animal, and environmental health through diverse interventions.
  • Ongoing translational efforts show potential for nanomedicine in controlling vector-borne diseases.

Abstract

Abstract Vector-borne and zoonotic diseases (VBZDs) remain a critical global health challenge, disproportionately affecting low- and middle-income countries and driving significant morbidity, mortality, and economic loss. This review synthesizes emerging evidence on nano-enabled smart drug delivery system (SDDS) within the One Health framework, emphasizing their role in advancing targeted therapy, controlled release, and theranostics for VBZD management. Nano-enabled platforms such as liposomes, polymeric nanoparticles, nanogels, metal–organic frameworks, and biomimetic carriers are designed for stimuli-responsive and site-specific delivery, enhancing therapeutic precision, lowering dosing frequency, and reducing the risk of drug resistance. Controlled-release formulations of agents such as artemisinin derivatives, amphotericin B, and ivermectin have demonstrated superior efficacy in the treatment of malaria and leishmaniasis, and in vector control applications. Targeted delivery strategies extend beyond human therapies to address viral reservoirs, infected macrophages, and arthropod vectors, highlighting the cross-species applications central to One Health. Theranostic innovations combine imaging and therapy to enable early disease detection, real-time monitoring, and the design of adaptive treatment strategies. Applications span human, animal, and environmental domains, from nanovaccines and veterinary antimicrobials to nanoparticle-based larvicides and biosensors for vector surveillance. Future directions underscore the integration of AI-driven nanodesign, scalable and eco-friendly synthesis, and harmonized regulatory frameworks to increase accessibility in resource-limited settings. Although clinical trials are limited, ongoing translational efforts indicate the transformative potential of nanomedicine in VBZD control. Ultimately, integrating nano-enabled SDDS into a One Health framework provides a sustainable and collaborative approach to reduce the global burden of zoonotic and vector-borne diseases.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Okesanya et al. (2026) studied this question.

synapsesocial.com/papers/698586238f7c464f2300a091https://doi.org/10.1186/s44280-026-00107-4
Ask AI
Helpful
Bookmark
Share
View Full Paper